Talk:GW Pharmaceuticals: Difference between revisions

Content deleted Content added

Inline

Revision as of 03:41, 4 February 2016

This article has not yet been rated on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Cannabis Start‑class Mid‑importance

	Cannabis portal This article is within the scope of WikiProject Cannabis, a collaborative effort to improve the coverage of cannabis on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CannabisWikipedia:WikiProject CannabisTemplate:WikiProject CannabisCannabis articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Pharmacology Start‑class Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Companies Start‑class Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Start This article has been rated as Start-class on Wikipedia's content assessment scale.

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.

Brands Start‑class Low‑importance

	This article is within the scope of WikiProject Brands, a collaborative effort to improve the coverage of brands on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.BrandsWikipedia:WikiProject BrandsTemplate:WikiProject BrandsBrands articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Guild of Copy Editors

This article was copy edited by Paulmnguyen, a member of the Guild of Copy Editors, on January 18, 2014.Guild of Copy EditorsWikipedia:WikiProject Guild of Copy EditorsTemplate:WikiProject Guild of Copy EditorsGuild of Copy Editors articles

Indiscriminate list of patents

Why do you think some of this patents indiscriminate ?? explain yourself before mass deleting. Vjiced (talk) 20:50, 5 November 2012 (UTC)[reply]

See WP:INDISCRIMINATE. Encyclopedia articles are not indiscriminate collections of information. We do not need to have a listing of every single patent that a company holds; if we did that for larger companies... well, this one is already absurdly long. --Aurochs (Talk | Block) 21:16, 5 November 2012 (UTC)[reply]

Also, in general, the fact that a company holds a patent is not in itself notable enough to include in an article. Lots of companies have patents. Further, the long list of patents makes the article significantly less readable. It's simply not a good thing to have for too many reasons. --Aurochs (Talk | Block) 21:26, 5 November 2012 (UTC)[reply]

Products in Development

Currently GW pharmacuticals are researching products for Cancer Pain ^[1]

References

^ pharmacuticals, G W. Products Pipline. GW pharmacuticals http://www.gwpharm.com/product-pipeline.aspx. Retrieved 18 November 2013. {{cite web}}: Missing or empty |title= (help)

Products in development redux

This needs to be toned down (saying that unapproved drugs "will be used to treat X" is promotional) and sourced to independent sources, as opposed to the company's website or conference abstracts (which are generally from the company for drugs in this stage of development) We also use generic names, not company brand names. We also look for secondary sources (conference abstracts are very primary sources)

Epidiolex

In 2015 GW Pharmaceutical was developing Epidiolex, an investigational cannabidiol liquid drug for epileptic children.^[1] It will be used to treat two orphan conditions, Dravet and Lennox-Gastaut syndromes.^[2] Phase 3 clinical trials for Epidiolex were conducted in 2015.^[3]^[4]^[5]

References

^ "GWPharma – Epidiolex". www.gwpharm.com. Retrieved 2016-02-03.
^ Butticè, Claudio (December 9, 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved February 3, 2016.
^ N. Jones, T. Hill, C. Stott, S. Wright. "Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals' Cannabidiol in the Anticonvulsant Screening Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)
^ Devinsky O.; et al. "Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03. {{cite web}}: Explicit use of et al. in: |last= (help)
^ Michael Oldham, Joseph Sullivan, Nilika Singhal, Nicole Tilton, Maria Cilio. "Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

-- Jytdog (talk) 03:41, 4 February 2016 (UTC)[reply]

[1] rmacuticals, G W. Products Pipline. GW pharmacuticals http://www.gwpharm.com/product-pipeline.aspx. Retrieved 18 November 2013. {{cite web}}: Missing or empty |title= (help)

[2] "GWPharma – Epidiolex". www.gwpharm.com. Retrieved 2016-02-03.

[3] Butticè, Claudio (December 9, 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved February 3, 2016.

[4] N. Jones, T. Hill, C. Stott, S. Wright. "Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals' Cannabidiol in the Anticonvulsant Screening Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

[5] Devinsky O.; et al. "Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03. {{cite web}}: Explicit use of et al. in: |last= (help)

[6] Michael Oldham, Joseph Sullivan, Nilika Singhal, Nicole Tilton, Maria Cilio. "Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

[1]

[1]

[2]

[3]

[4]

[5]

@@ Line 19: / Line 19: @@
 Currently GW pharmacuticals are researching products for Cancer Pain <ref>{{cite web|last=pharmacuticals|first=G W|url=http://www.gwpharm.com/product-pipeline.aspx|work=Products Pipline|publisher=GW pharmacuticals|accessdate=18 November 2013}}</ref>
 {{reflist-talk}}
+== Products in development redux ==
+This needs to be toned down (saying that unapproved drugs "will be used to treat X" is promotional) and sourced to independent sources, as opposed to the company's website or conference abstracts (which are generally from the company for drugs in this stage of development)   We also use generic names, not company brand names.   We also look for secondary sources (conference abstracts are very primary sources)
+;Epidiolex
+In 2015 GW Pharmaceutical was developing Epidiolex, an investigational cannabidiol liquid drug for epileptic children.<ref>{{Cite web|title = GWPharma – Epidiolex|url = http://www.gwpharm.com/Epidiolex.aspx|website = www.gwpharm.com|access-date = 2016-02-03}}</ref> It will be used to treat two [[rare disease|orphan conditions]], [[Dravet syndrome|Dravet]] and [[Lennox–Gastaut syndrome|Lennox-Gastaut]] syndromes.<ref>{{Cite web|url = http://medsnews.com/health/therapeutic-cannabis-for-children-a-possible-new-treatment-for-epilepsy/|title = Therapeutic Cannabis for children – a possible new treatment for epilepsy|date = December 9, 2015|access-date = February 3, 2016|website = Meds News|publisher = |last = Butticè|first = Claudio}}</ref> [[Phase 3 clinical trial]]s for Epidiolex were conducted in 2015.<ref>{{Cite web|title = Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals’ Cannabidiol in the Anticonvulsant Screening Program |url = https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2325855 |website = www.aesnet.org|access-date = 2016-02-03|last = N. Jones, T. Hill, C. Stott, S. Wright|publisher = American Epilepsy Society}}</ref><ref>{{Cite web|title = Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program|url = https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2414222|website = www.aesnet.org|access-date = 2016-02-03|publisher = American Epilepsy Society|last = Devinsky O., et al}}</ref><ref>{{Cite web|title = Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies|url = https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2328389|website = www.aesnet.org|access-date = 2016-02-03|publisher = American Epilepsy Society|last = Michael Oldham, Joseph Sullivan, Nilika Singhal, Nicole Tilton, Maria Cilio}}</ref>
+{{reflist-talk}}
+-- [[User:Jytdog|Jytdog]] ([[User talk:Jytdog|talk]]) 03:41, 4 February 2016 (UTC)